Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (NCT04851964), a randomized phase 3 study. The primary outcome is Change From Baseline in Total Nasal Polyp Score at Week 52.

2. Clinical Question

The primary measure is a score from nasal endoscopy, with higher scores indicating greater symptom severity. The registry reports a larger mean reduction from baseline in the tezepelumab group than in the placebo group. The randomized comparison is expressed as a difference in least-squares means, with a confidence interval and a p-value from an ANCOVA analysis.

The clinical question is also situated within a treatment context: both groups received background intranasal corticosteroid, so the contrast concerns adding tezepelumab rather than replacing that background treatment. The registry lists additional outcomes involving smell, disease-specific symptoms, imaging, lung function, and decisions about surgery or systemic corticosteroids. These outcomes broaden the description of the trial but do not replace the prespecified primary question.

The registry record does not report the criteria used to define severe disease or further details of eligibility. Those details should not be inferred from the condition name or outcome descriptions.

3. Trial Design

WAYPOINT is recorded as a Phase 3, multicentre, randomized, double-blind, parallel-group, placebo-controlled study. Masking is classified as quadruple in the registry; the specific people or roles covered by that label are not reported in the registry record. The listed enrollment is 416. The record identifies AstraZeneca as the sponsor and lists the study status as completed.

The intervention groups received subcutaneous tezepelumab or placebo every 4 weeks. Each was added to background mometasone furoate or an equivalent intranasal corticosteroid. This shared background treatment makes the randomized contrast an evaluation of tezepelumab added to background therapy, compared with placebo added to background therapy.

The registry lists the study start as 2021-04-22 and primary completion as 2024-09-23. The primary outcome timeframe is baseline to Week 52. Its analysis population is described as all randomized participants who received at least one dose of investigational product. The posted outcome groups contain 203 participants in the tezepelumab group and 205 in the placebo group; the registry record does not give a fuller account of how participants contributed to each analysis.

Randomization and masking are design features intended to reduce systematic differences in treatment assignment and outcome assessment. They do not, by themselves, establish that every potential source of bias was eliminated. The registry record does not report the allocation sequence details, the masking procedures, the sample-size justification, or a fuller protocol description. It also does not report an interim-analysis plan. These details should not be inferred from the trial title or design labels.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: All patients completed a 5-week run-in period during which inclusion/exclusion criteria were assessed, medical history was recorded, nasal endoscopy and biopsy and CT scan were performed, and patient-reported outcomes (PROs) and clinical laboratory tests were performed.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Full analysis set (All randomized participants who received at least one dose of IP).

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: All participants who were randomized and received any IP were included in the full analysis set.

6. Primary Endpoint

The registry lists the primary outcome as Change From Baseline in Total Nasal Polyp Score at Week 52, measured over Baseline to Week 52.

The primary endpoint is change from baseline in total nasal polyp score at Week 52. The score is the sum of the right and left nostril scores, with a maximum of 8. Each side is assessed on a scale from 0 to 4 using nasal endoscopy, and higher scores indicate greater symptom severity. The description states that the endoscopies are centrally read by two independent physician reviewers.

A change score expresses how the measured outcome at follow-up differs from baseline. A more negative change in this endpoint indicates a greater reduction in the score, which is the direction associated with lower severity on the stated scale. The registry reports group least-squares means rather than only raw group averages. These adjusted means are used in the posted ANCOVA comparison.

Endoscopic scoring provides a structured measure of nasal polyp burden, rather than relying solely on participants’ reports of symptoms. Central reading by independent reviewers is intended to standardize assessment across study sites. That feature can support consistent measurement, although the registry record does not report reader agreement or other measurement-quality results.

The endpoint is useful for asking whether the groups differed in the measured polyp score over the specified follow-up. It does not, by itself, capture every aspect of chronic rhinosinusitis, nor does a score difference establish the size of any broader patient-perceived benefit. Other outcomes in the registry address symptoms, smell, imaging, and treatment-related events, but they remain distinct measures.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The primary outcome is continuous: it is a numerical score, and the posted result summarizes change in that score. The registry reports least-squares means for each group and an ANCOVA comparison of those means. ANCOVA is a general statistical method for comparing group outcomes while accounting for specified covariates. The registry record does not identify the covariates used in the primary analysis, so their role cannot be described in more detail.

A least-squares mean is a model-based group estimate rather than necessarily the unadjusted arithmetic average of the observed scores. The reported difference in least-squares means is the contrast between those model-based estimates. A negative contrast indicates a more negative mean change in the tezepelumab group, consistent with a greater reduction in the score because higher score values represent greater severity.

A confidence interval communicates uncertainty around an estimate. In general, it is constructed using a statistical procedure that, under its assumptions, would cover the underlying quantity at the stated rate across repeated applications. It is not a range that guarantees the true effect lies within it. The primary estimate is reported with a 95% confidence interval. Its placement entirely below zero supports a difference in the direction of a larger reduction in the tezepelumab group.

The p-value is a measure of how unusual results at least as incompatible with the null hypothesis would be if that hypothesis and the analysis assumptions held. It is not the probability that the null hypothesis is true, and it does not measure the probability that the result is due to chance. The reported primary p-value is p <.0001. The registry classifies the primary analysis as a superiority analysis; that label describes the statistical comparison, not a complete assessment of clinical value.

For the listed binary secondary outcomes, the registry gives participant percentages and confidence intervals. The additional recalculations express the group contrast as an unadjusted risk difference, using posted summary information. A risk difference compares the observed event proportions between groups on an absolute scale. Because these are simple unadjusted recalculations, they do not necessarily reproduce the sponsor’s model-based analyses or their assumptions.

The sponsor’s secondary analyses are reported as Cox regression hazard ratios. In general, a hazard ratio compares event rates over time, accounting for the timing of events under the model’s assumptions. It is not the same quantity as a risk difference, which contrasts the proportions with an event over the specified follow-up. The registry lists both types of analysis for the highlighted secondary outcomes; they should be interpreted as distinct estimands rather than alternative labels for the same result.

Confidence intervals are also reported for the secondary group percentages. Such intervals indicate uncertainty in each group estimate, whereas a confidence interval for a contrast directly addresses the between-group difference. For binary outcomes, estimates may be unstable when events are uncommon; generally, fewer events leave less information for estimating event frequency. The registry record does not provide a detailed account of any small-sample methods used for the reported analyses.

Planning illustrations based on observed effects are not observed power calculations and do not explain the trial’s original design. The listed assumptions for those illustrations are a two-sided significance level of 0.05, equal allocation, and a normal approximation; the assumed effect is a stated fraction of the observed effect. For time-to-event illustrations, the listed quantity is a total number of events; other illustrations are participants per arm. Such calculations are conditional on their assumptions and observed effect estimates. The trial’s own sample-size justification is not reported in the registry record.

General statistical caution applies to all these analyses: estimates depend on the outcome definition, analysis population, model assumptions, handling of missing observations, and multiplicity procedures. The registry reports the primary population definition and selected model labels, but it does not report all these implementation details. No unreported procedures should be inferred from the use of ANCOVA or Cox regression alone.

10. Analyses Reported by the Sponsor

The primary result is reported as an ANCOVA comparison of least-squares means: the difference was -2.078, with a 95% confidence interval from -2.399 to -1.757 and p <.0001. The posted primary result is therefore the sponsor’s reported model-based analysis, rather than a separate recalculation from group summaries. No discrepancy is flagged between the posted primary result and the available analysis information.

For the highlighted secondary outcomes, the registry reports sponsor analyses using Cox regression and hazard ratios. The accompanying recalculations use posted summary statistics to produce unadjusted risk differences. These approaches differ: the hazard ratio incorporates event timing under a model, while the risk difference compares event proportions over the stated follow-up. Agreement in the general direction does not make the estimates equivalent.

When a discrepancy between a sponsor analysis and a recalculation is flagged, the sponsor’s own analysis takes precedence. No discrepancy is flagged in this record. The recalculations are best read as supplementary, transparent comparisons of the posted summaries; they do not replace the sponsor’s reported analysis or establish that the model assumptions are the same.

The registry record does not provide enough information to independently reproduce the sponsor’s models in full, including all covariates and analysis details. Accordingly, the sponsor-reported estimates and their stated confidence intervals and p-values remain the primary statistical account of those analyses.

11. Multiplicity, Missing Data and Analysis Populations

The primary analysis population is described as the full analysis set, comprising all randomized participants who received at least one dose of investigational product. This definition is reported for the primary endpoint. The registry record does not give a fuller account of analysis-population rules for every secondary outcome, or clarify how participants with incomplete outcome data were handled.

Missing outcome data can affect estimates if participants with missing measurements differ from those with observed measurements. Statistical methods may use assumptions or sensitivity analyses to address that possibility, but the registry record does not report the missing-data procedures or sensitivity analyses for the primary or secondary outcomes. The amount and pattern of missing data are also not reported in the results summarized in the record. It is therefore not possible to assess from this information alone how strongly missingness could affect the estimates.

Multiplicity arises when investigators assess several outcomes or make several statistical comparisons. Even when each individual test uses a conventional threshold, testing many hypotheses can raise the overall chance of at least one false-positive result. Trials may use a prespecified hierarchy or statistical adjustment to manage this issue. Whether either approach was used for the secondary outcomes is not reported in the registry record. The primary outcome’s reported p-value should not be assumed to account for the full family of secondary comparisons.

The registry lists a primary endpoint and multiple secondary outcomes, but the inferential relationship among them is not described in enough detail to determine which secondary results were intended as confirmatory. The record also does not report an interim-analysis plan. These omissions limit reconstruction of the full statistical testing strategy; they do not show that a procedure was absent from the trial protocol.

These reporting gaps matter when interpreting precision and strength of evidence. The primary estimate and its confidence interval describe the reported model-based comparison, while missing-data and multiplicity procedures can affect how broadly that result should be interpreted. Neither issue can be resolved by the numerical result alone.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: asthma (1.0%), appendicitis (0.5%), arthritis bacterial (0.5%), covid-19 pneumonia (0.5%), escherichia urinary tract infection (0.5%).

During the treatment periods, the registry reports serious adverse events in 11 participants in the tezepelumab group and 14 participants in the placebo group. The corresponding groups at risk are listed as 203 and 205. The record reports no deaths in the tezepelumab group and 1 death in the placebo group. It also lists other, non-serious adverse events in 119 participants in each group.

The registry separately lists a run-in period, with 408 at risk, no serious adverse events, and 20 other adverse events. These run-in figures describe a different period from the randomized treatment-group figures and should not be combined with them as if they were another randomized arm.

Serious adverse event counts describe events classified as serious under the trial’s reporting definitions; they do not by themselves establish that an event was caused by study treatment. The registry record does not report event relatedness in the figures. It lists asthma as a serious event term at 1.0%, and several other terms at 0.5%, but these summaries do not provide a complete account of clinical context or individual event courses.

Comparisons of adverse event counts are descriptive. They do not establish equivalent safety profiles, and the counts alone do not quantify comparative risk with an adjusted analysis. The registry record does not report the methods for safety comparisons in these results.

13. What the Result Does, and Does Not, Mean

The central statistical finding is a difference in change in total nasal polyp score at Week 52, with the estimated contrast favoring a larger reduction in the tezepelumab group. The confidence interval lies below zero, and the reported p-value is small under the ANCOVA analysis. The secondary outcomes highlighted in the registry generally point in a compatible direction for surgery decisions and systemic corticosteroid use.

This is evidence about group averages and event summaries in the trial population, not a prediction of the outcome for an individual participant. Group estimates do not imply that every participant had the same response. Nor does a statistically clear difference automatically indicate how important the difference would be to participants; the registry record does not report a threshold for clinical importance for the primary score.

The primary endpoint measures endoscopic polyp score, not every symptom or consequence of chronic rhinosinusitis with nasal polyposis. Secondary outcomes extend the assessment to other domains, but they remain separate measures and are subject to their own uncertainty and multiplicity concerns. The registry record does not report all analysis details needed to fully assess missing data, adjustment for multiple testing, or the robustness of each secondary result.

The results describe tezepelumab added to background intranasal corticosteroid compared with placebo added to background intranasal corticosteroid. They do not isolate the effect of treatment without that background therapy. The record also does not support conclusions about populations or treatment settings beyond the study’s participants and design.

These findings are statistical descriptions of the posted trial results. They do not, on their own, constitute medical advice, establish an individual treatment decision, or answer every question about benefits and harms.

14. Why This Trial Matters Statistically

The trial offers a clear example of how a continuous primary endpoint can be reported and interpreted alongside secondary event outcomes. The primary comparison uses change in an endoscopic score, least-squares means, an ANCOVA contrast, and a confidence interval. This makes it possible to distinguish the estimated size and direction of a group difference from the uncertainty around that estimate.

It also illustrates why the analysis method matters. A model-based difference in least-squares means addresses the primary score comparison, while a hazard ratio and an unadjusted risk difference describe secondary event outcomes in different ways. Treating these estimates as interchangeable would obscure the distinct questions they answer.

The secondary results add context because their broad direction is consistent with the primary result, but they do not eliminate the need to consider multiplicity. When several outcomes are assessed, a reader needs to know how the trial’s testing strategy controlled or prioritized those comparisons. That information is not reported in the registry record, which limits the strength of confirmatory conclusions drawn from secondary analyses.

The record also illustrates the importance of distinguishing statistical evidence from clinical importance. A confidence interval can show that a group contrast is estimated with substantial separation from zero, yet the clinical meaning of a score change requires context beyond its p-value. The posted outcomes should therefore be read as complementary pieces of evidence, with the primary endpoint central and secondary outcomes supportive but less definitive where multiplicity procedures are unclear.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific details needed for a fuller appraisal are not reported in the registry record. These include the primary model’s covariates, detailed missing-data procedures, sensitivity analyses, and how analysis populations were defined for outcomes beyond the primary endpoint. Without these details, the degree to which results depend on modeling and data-availability assumptions cannot be assessed from the registry results alone.

The record does not report the multiplicity strategy for the secondary outcomes, the sample-size justification, or an interim-analysis plan. Consequently, the confirmatory status of individual secondary findings and the intended balance of statistical power across outcomes are unclear. Planning illustrations based on observed effects should not be confused with the trial’s design justification.

The reported primary outcome is a score assessed by central readers. The record describes two independent physician reviewers and the score scale, but does not report reader agreement or information about measurement reliability. The registry also does not provide the clinical-importance threshold used, if any, for interpreting changes in the score.

Safety results are presented as counts, without the additional detail needed to attribute events to study treatment or compare event risks using an adjusted analysis. The record does not report the relevant event definitions and adjudication procedures in the figures. Counts alone are not sufficient to establish that safety profiles are the same or different.

Finally, the results concern the studied population and the comparison of tezepelumab or placebo on a background intranasal corticosteroid. The registry information does not establish how results would generalize to other populations, treatment contexts, or follow-up periods.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis — NCT04851964.
• Registry record last updated 2026-01-27; status last verified 2026-01.
• Results first posted 2026-01-27.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

WAYPOINT is a completed, randomized, double-blind, parallel-group, placebo-controlled Phase 3 study of tezepelumab in participants with severe chronic rhinosinusitis with nasal polyposis. The registry lists enrollment of 416 and identifies AstraZeneca as sponsor. Participants received tezepelumab or placebo every 4 weeks, each added to background mometasone furoate or an equivalent intranasal corticosteroid.

The primary endpoint was change from baseline in total nasal polyp score at Week 52. The reported difference in least-squares means was -2.078, with a 95% confidence interval from -2.399 to -1.757 and p <.0001. The negative contrast indicates a larger mean score reduction in the tezepelumab group.

Highlighted secondary outcomes generally showed lower participant percentages for surgery decisions and systemic corticosteroid use in the tezepelumab group. Their interpretation is limited by uncertainty about multiplicity procedures and other analysis details not reported in the registry record. Safety counts are descriptive and do not, by themselves, establish event causation or comparative safety.